Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives

Hua Zhang, 1 Xufeng Dai, 1 Yan Qi, 1 Ying He, 1 Wei Du, 2 and Ji-jing Pang 1,2

1 Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China
2 Department of Ophthalmology, University of Florida, Gainesville, FL, USA

Correspondence should be addressed to Ji-jing Pang; jpang@ufl.edu

Received 6 August 2014; Accepted 9 September 2014

Academic Editor: Xinhua Shu

Large amounts of data have shown that HDACis also have important neuroprotective effects in the treatment of diseases of the nervous system [10–13]. HDACis are known to reduce apoptosis, increase cell survival, regulate the expression of various neurotrophic factors, and enhance anti-inflammatory responses [10, 11, 14–16]. Apoptosis of retinal photoreceptor cells is a main feature of retinal degenerative diseases [17, 18], and neurotrophic factors have positive protective effects on retinal degenerative diseases [19, 20]. Thus, HDACis may have therapeutic potentials for retinal degenerative diseases. In this paper, we will focus on the progress of studies on using HDACis in the prevention and treatment of retinal degeneration.

2. Histone Deacetylase

There are 18 HDACs in human, and they are divided into four different classes based on their homology to yeast protein RPD3, Hda1, Sir2, and HOS3 (Table 1) [3]. Classes I, II, and IV HDACs are Zn²⁺-dependent and homologous to the yeast RPD3, Hda1, and HOS3, respectively, whereas Class
Table 1: Class, homology, catalytic subunit, compound, and localization of HDACs.

| Class | Homology | Catalytic subunit | Compound | Localization | References |
|-------|-----------|-------------------|-----------|--------------|------------|
| I     | RPD3      | Zn$^{2+}$         | HDACs 1–3 and 8 | Nucleus      | [3, 21]    |
| IIA   | Hda1      | Zn$^{2+}$         | HDACs 4, 5, 7, and 9 | Nucleus/cytoplasm | [3, 21]    |
| IIB   | Hda1      | Zn$^{2+}$         | HDACs 6 and 10 | Mostly cytoplasm | [3, 21]    |
| III   | Sir2      | NAD$^+$           | SIRT1–7   | Nucleus/cytoplasm | [3, 21]    |
| IV    | HOS3      | Zn$^{2+}$         | HDAC II   | Nucleus/cytoplasm | [3, 21]    |

Table 2: Class, common compound, HDAC target, and main functions of HDACs.

| Class     | Compound | HDAC target | Function          | References |
|-----------|----------|-------------|-------------------|------------|
| Hydroxamic acids | TsA      | Classes I and II | A, D, GA, P, CP, R, NG, and AI | [21, 22, 41, 42] |
|           | SAHA     | Classes I and II | A, CP, S, TR, and AI | [21, 67, 69, 70, 74] |
|           | LBH589   | Classes I and II | A, GA, TR, and P   | [21, 33, 89] |
|           | PXD101   | Classes I and II | A, GA, and TR     | [21, 33] |
| Cyclic peptides   | FK228    | Class I     | A, GA, D, and TR  | [21, 33, 90] |
| Benzamides       | MS-275   | HDACs 1, 2, and 3 | A, D, S, and GA  | [21, 77] |
|           | MGCD0103 | Class I     | A, TR, AI, and GA | [21, 91, 92] |
| Aliphatic acids  | VPA      | Classes I and IIA | A, AI, TR, S, and GA | [10, 11, 21, 51] |
|           | PBA      | Classes I and IIA | A, D, and GA     | [21, 93, 94] |
|           | NaB      | Classes I and IIA | A, D, GA, AI, TR, S, and NG | [11, 15, 21, 57] |

A: cell apoptosis/death; AI: anti-inflammatory effect; TR: transcriptional regulation; NG: neurogenesis; S: cell survival; CP: cell-cycle progression; P: proliferation; R: regeneration; D: differentiation; GA: growth arrest.

III HDACs are NAD$^+$-dependent and homologous to yeast Sir2. Class I HDACs include HDACs 1, 2, 3, and 8, which are localized in the nucleus [21]. Class I HDACs can regulate neurogenesis, cell senescence, proliferation, differentiation, and embryonic development [22–25]. HDACs 4, 5, 6, 7, 9, and 10 make up Class II HDACs, which are localized both in nucleus and in cytoplasm. Class II HDACs consist of two subclasses: Class IIa (HDACs 4, 5, 7, and 9) and Class IIb (HDACs 6 and 10). Compared to Class I HDACs, Class II has more tissue-specific functions, such as cardiac, microtubule, and chondrocyte differentiation defects [26–28]. Class III HDACs consist of sirtuins (SIRT1–7), whereas Class IV contains only HDAC11 and relatively little is studied about this subtype [3, 21]. In this paper, we introduce mainly the progress of Class I and II HDACs inhibitors in the treatment of retinal degenerative diseases.

### 3. Histone Deacetylase Inhibitor

According to the different chemical structures, HDACis can be divided into four classes, which include hydroxamic acids, cyclic peptides, benzamides, and aliphatic acids [21, 29] (Table 2). Hydroxamic acids can inhibit Class I and Class II HDACs, which include trichostatin A (TsA), vorinostat (SAHA), panobinostat (LBH589), and belinostat (PXD101) [30–33]. Cyclic peptides, romidepsin (FK228), have the most complex structure. Benzamides include entinostat (MS-275) and mocetinostat (MGCD0103). Common aliphatic acids include valproic acid (VPA), sodium butyrate (NaB), and phenylbutyrate (PBA) [34]. HDACis can cause hyper-acetylation of histone and nonhistone proteins and further regulate transcription process, cellular microenvironment, and immune responses [35]. HDACis have an important role in the inhibition of tumor cell proliferation and in the induction of cell differentiation [36–38]. Studies have shown that HDACis can promote the transcription of retinal photoreceptor genes by histone acetylation, resulting in effectively reversing the course of retinal photoreceptor cell degeneration [39–41]. Several HDACis have been approved for clinical trials, such as SAHA, FK228, Mgcd0103, LBH589, PXD-101, and MS-275 [35]. Currently, the studies of HDACis focus mainly on cancer therapy, cell differentiation, neuro-protection, and heterochromatin fields, and as yet, research has just started in retinal degeneration.

### 4. Trichostatin A

TsA is a hydroxamic acid, a Class I and II HDACi, which is the first natural hydroxamic acid found to inhibit HDACs, and is one of the most studied HDACis, especially in the retina [31]. TsA has an important role in the prevention and treatment of neurodegenerative conditions [12, 42]. TsA can regulate the levels of apoptosis-related proteins and improve neurological performance in the rat permanent middle cerebral artery occlusion (pMCAO) model of stoke [11] (Table 3).

TsA suppressed TNF-α expression and signaling in retina from rat ischemic injury and changed the level of acetylated histone 3 (AcH3) and the secretion of...
Table 3: Function and molecular targets of common HDACs in nervous system diseases.

| HDACi | Function | Molecular targets | References |
|-------|----------|-------------------|------------|
| TSA   | A        | Bcl-2 and apaf-1  | [11]       |
| AI    | IL-6, TNF-α, and NF-kappaB | | [42] |
| TR    | HSP70, AcH3, AcH4, PI3K/Akt, BDNF, and NF-κB | | [11] |
| VPA   | A        | Caspase 3 and HSP70 | [10, 11, 51, 52] |
| AI    | OX-42, ED-1, and iNOS | | [11] |
| TR    | HSP70, AcH3, pERK, bcl-2, pCREB, pAkt, bcl-xl, NF-κB, and JNK | | [10, 11, 51, 52] |
| NaB   | AI       | OX-42, ED-1, and iNOS | | [11] |
|       | N        | BDNF-TrkB         | [16]       |
|       | A        | Caspase 3 and HSP70 | | [11] |
| TR    | HSP70, AcH3, AcH4, Sp1, p21, and p27 | | [11, 67] |

A: cell apoptosis/death; AI: anti-inflammatory effect; TR: transcriptional regulation; N: neurogenesis.

Table 4: Function and molecular targets of common HDACs in retinal degenerative diseases.

| HDACi | Function | Molecular targets | References |
|-------|----------|-------------------|------------|
| TsA   | CP       | Wnt signaling and notch signaling | [22] |
|       | P        | Notch signaling, cyclinD1, CDK, and p-Rb | [22] |
| A     | Caspase 3, apaf-1, and PARP | | [41, 49] |
| R     | RARβ and AcH3K9 | | [46] |
| AI    | TNF-α    | | [43] |
| TR    | AcH3, TNF-α, MMP-1, and MMP-3 | | [43] |
| VPA   | A        | Caspase 3, Caspase 12, apaf-1, HSP70, and cytochrome C | | [14, 56, 58, 59] |
| S     | Caspase 3, CREB, and pERK1/2 | | [14, 56, 58, 59] |
| TR    | HSP70, AcH3, cytochrome C, GRP78, CHOP, TrkB, and pERK1/2 | | [14, 56, 58, 59] |
| NaB   | A        | BDNF-TrkB and AcH3K14 | | [58] |
| S     | AcH3 and AcH4 | | [57] |
| TR    | AcH3, AcH4, Akt, and Erk | | [57] |

A: cell apoptosis/death; AI: anti-inflammatory effect; TR: transcriptional regulation; S: cell survival; CP: cell-cycle progression; P: proliferation; R: regeneration.

matrix metalloproteinase-1 (MMP-1) and MMP-3 [43]. TsA also improved the electroretinography (ERG) responses in ischemic injury retina [43, 44]. In the zebrafish retina, TsA can regulate cell-cycle progression and neurogenesis by Wnt and notch signaling pathways [22]. TsA also regulates the apoptotic process by upregulating the expression of apoptotic protease activating factor-1 (apaf-1) and caspase 3 in the developing mouse retina [41]. TsA treatment attenuated the downregulation of Fem1cR3 gene expression, delayed the progressive damage, and reduced apoptosis to retinal ganglion cells (RGCs) in aged DBA/2J mice [45]. TsA induced axonal regeneration by inducting expression of AcH3 and retinoic acid receptor β (RARβ) in adult rat RGCs [46], which play an important role in development and differentiation [47]. In in vitro retinal explants of retinal degeneration 1 (rd1) mice, TsA treatment decreased the rate of cells apoptosis, enhanced the photoreceptor cell survival, and prevented photoreceptor degeneration by suppressing poly(ADP-ribose) polymerase (PARP) activity, which promoted cell death of rd1 retina [39, 48, 49]. However, in retinal explants of normal mice, TsA inhibited the expression of pro-rod transcription factors Otx2, Nrl, and Crx and the development of rod photoreceptor cells [40], which had the opposite effect compared with retinal degeneration mice. TsA treatment inhibited the proliferation and the TGF-β2-induced epithelial-mesenchymal transition (EMT) pathway by downregulating TGF-β/Akt, MAPK, ERK1/2, and notch signaling pathways in human retinal pigment epithelial (RPE) cells. This may have a clinical value in the prevention and treatment of proliferative vitreoretinopathy (PVR) [50] (Table 4).

5. Valproic Acid

As a short chain fatty acid, VPA is a broad-spectrum HDACi and is currently used widely as an anticonvulsant drug. Many studies have shown that VPA has neuroprotective effects against the damage of central nervous system (Table 3). VPA has been shown to reduce brain damage in a rat transient focal cerebral ischemia model and to improve functional outcome by reducing caspase 3 activation and increasing heat-shock protein 70 (Hsp70) levels [10]. In a rat pMCAO stroke model, VPA increased the anti-inflammatory effect by inhibiting inducible nitric-oxide synthase (iNOS) and OX-42, regulated the levels of apoptosis-related proteins, and improved neurological performance [11]. In rat intracerebral hemorrhage (ICH) model, VPA reduced perihematomal cell death and activities of caspases 3, 8, and 9 and alleviated inflammation by regulating transcriptional activation [51]. Under hypoxic conditions, VPA treatment prevented neuron apoptosis, increased levels of AcH3, activated NF-κB, and reduced JNK activation in the primary rat hippocampal and cortical cultures in vitro [52].
VPA has also an important role in protecting the RGCs (Table 4). In a rat ischemia/reperfusion (I/R) model, VPA prevented axon damage of RGCs [14, 53]. After I/R damage, VPA attenuated retinal neuron apoptosis by inhibiting the activation of caspase 3, upregulation of apaf-1, and release of cytochrome C. At the transcriptional level, VPA upregulated the expression of Hsp70 and enhanced acetylation of histone H3 and Hsp70 promoter [14]. VPA treatment prevented significantly the retinal histological damage and the loss of RGCs by reducing endoplasmic reticulum (ER) stress-induced apoptosis. VPA decreased the expression of C/EBP homologous protein (CHOP) and caspase 12 [33]. CHOP is a transcription factor involved in ER stress-induced apoptosis [54], whereas caspase 12 is a proapoptotic factor activated by ER stress [55]. After optic nerve crush (ONC) in rat, VPA has a neuroprotective effect by increasing RGCs survival and expression of pERK1/2, inhibiting caspase 3 activity, and inducing the DNA binding of cAMP response element binding protein (CREB) in the injured RGCs [56]. In purified rat RGCs, VPA enhanced cell survival and delayed spontaneous cell death [57]. In a rat model of ONC, VPA treatment can inhibit apoptosis of RGCs via the activation of brain-derived neurotrophic factor (BDNF) and tropomyosin-related kinase B (TrkB) signaling [58]. VPA can induce expression of HSP70 and attenuate the photoreceptor cell death induced by N-methyl-N-nitrosourea in mice [59]. In clinical trials of retinitis pigmentosa (RP), VPA may reduce the loss of photoreceptor cells. VPA has an effective therapeutic potential for RP, but efficacy and safety of VPA in the treatment of RP need to be assessed by further clinical trials [60].

6. Sodium Butyrate

Sodium butyrate (NaB) is a short chain fatty acid, which can increase histone acetylation levels, inhibit tumor cell proliferation, and promote tumor cell senescence and apoptosis [61–64]. NaB is widely used as an animal feed additive [65] and plays also an important role in the prevention and treatment of neurodegenerative conditions [12, 13] (Table 3). It has anti-inflammatory effects in rat brain-derived primary microglia cells [66]. In the ischemic brain of pMCAO rat, NaB stimulated neurogenesis and induced cell proliferation, migration, and differentiation by BDNF-TrkB signaling [15]. Like VPA, NaB also has anti-inflammatory effects and neuroprotective effects in the rat pMCAO stroke model [11]. NaB can induce the activation of BDNF promoter IV in the rat cortical neurons in vitro [16]. NaB can regulate G1-to-S cell cycle progression by cyclin-dependant kinase (cdk) inhibitors p21 and p27 in adult mouse neural stem cells (NSCs) [67].

In vitro, NaB can delay spontaneous cell death, enhance cell survival in purified rat RGCs, and increase levels of AcH3 and AcH4 [57]; it can also increase the level of AcH3 and induce morphological changes in Y79 cells, a retinoblastoma cell line [68]. After NaB treatment, original round morphology of Y79 cells changed into spindle or irregular morphology. After ONC injury in rat, NaB can promote survival of RGCs, increase ERG responses, upregulate phosphorylation of Akt and Erk, and increase hyperacetylation of histone H3K14 [58] (Table 4).

7. Other HDACis

SAHA, a hydroxamic acid derivative, is the first HDACi drug approved by the Food and Drug Administration (FDA) for the treatment of cancer in the United States [21]. In clinical trials, SAHA has been used to treat cutaneous T-cell lymphoma. Many studies have also shown that SAHA has neuroprotective effects [69–72]. Like NaB, SAHA can also regulate cell cycle progression by p21 and p27 in adult mouse NSCs [67] and SAHA also has a good protective effect in corneal haze and injury [73, 74]. SAHA can induce caspase-dependent apoptosis and reduce cell survival in human retinoblastoma (RB) cells [75, 76], MS-275, a synthetic benzamide derivative, which selectively inhibits HDACs 1, 2, and 3, is also a HDACi drug used in cancer treatment in clinical trials. Ms-275 can protect RGCs differentiation and survival following optic nerve injury in Thy-1 CFP mice [77].

8. Discussion

Retinal degenerative diseases, such as RP, Leber congenital amaurosis (LCA2), achromatopsia, juvenile macular degeneration, and cone-rod dystrophy, are the major blinding fundus diseases, and the pathogenesis of these diseases is very complex. Apoptosis of photoreceptor cells is a common feature of retinal degeneration, and a variety of stimuli, such as tumor necrosis factor (TNF), Fas ligands (FasL), mitochondria, and ER stress, can lead to cell death. These stimuli can cause caspase cascade, activate firstly the initiator caspases (caspase 8, 9, 10, and 12), further activate downstream effector caspases (caspase 3, 6, and 7), and lead to apoptotic cell death [55], whereas antiapoptotic HSP70, B-cell lymphoma-2 (Bcl-2), and B-cell lymphoma-extra large (Bcl-xl) can inhibit this caspase cascade [11, 55]. HDACis can upregulate the expression of antiapoptotic HSP70 and Bcl-2 and downregulate the expression of proinflammatory TNF-α [11, 78, 79]. In retinal diseases, studies showed that HDACis treatment upregulated the expression of Hsp70, downregulated the expression of caspase 1 and caspase 3, inhibited the translocation of cytochrome C and activation of Akt and Erk, increased the rate of cell survival, and decreased the apoptosis process [14, 49, 58]. Akt and Erk signaling can inhibit apoptosis by preventing cytochrome C release [55]. VPA, NaB, and TSA regulate the activation of Akt and Erk signaling and further regulate the apoptosis process [50, 58].

Some factors, such as growth factors and cytokines, can activate PI3K/Akt, PKC, and Erk signaling, prevent the expression of antiapoptotic glycoprotein synthase kinase-3 (GSK-3), forkhead in rhabdomyosarcoma (FKHR), Bcl-2 antagonist of cell death (Bad), and Bcl-xl, and increase cell survival [55]. Neurotrophic factors also regulate the apoptosis of photoreceptor cells in the development of the visual system [55]. Ciliary neurotrophic factor (CNTF) can control photoreceptor differentiation in rat retina [80]. HDACis, VPA, NaB, and TSA increased the expression of glial cell
line-derived neurotrophic factor (GDNF) and BDNF in the rat astrocytes [81]. In rd1 retinal explants, BDNF and CNTF activate the Erk, Akt, and CREB pathways to decrease the apoptosis of photoreceptor cells [82]. After ONC in rat, HDACis activate BDNF-TrkB signaling, upregulate the level of antiapoptotic Bcl-2, and downregulate the activation of caspase 3 [58]. These data suggest that HDACis have the potential to alter gene expression of neurotrophic factors and further regulate the apoptosis of photoreceptor cells in the retina.

Gene regulation is also an important function of HDACis in retinal degenerative diseases. Since the acetylation/deacetylation of histone and nonhistone proteins has extensive effects on gene regulation, upregulation of acetylation caused by HDACis would likely lead to significantly altered transcription of genes related to retinal degeneration. HDACis have been shown to inhibit the expression of FasL and proinflammatory cytokine interleukin-6 (IL-6), increase the acetylation of histone H3, activate the transcription of downstream genes Akt, Erk, CREB, and HSP70, and thus unregulated the levels of antiapoptotic proteins Bcl-2 and Bcl-xl, and eventually lead to the downregulation caspase 3 [11,51]. In retinal degenerative diseases, HDACis treatment can induce acetylation of histone H3, regulate Akt, Erk, CREB, and TrkB signaling, and further inhibit the activity of caspase 3 [14,56,58]. HDACis also can regulate the expression of neurotrophic factors [58].

Several factors can lead to the death of photoreceptor cells. In addition to spontaneous apoptosis and retinal degeneration, certain ocular adverse events, such as surgery and gene therapy, can also lead to the loss of photoreceptor cells. Gene therapy has broad application prospects and has achieved great success in the treatment of LCA2 [83]. It has been reported that gene therapy can restore visual function in animal models and clinical trials; but apoptosis of remaining photoreceptor cells could progress slowly and continuously in treated areas, and the restored visual function by gene therapy gradually weakens [83–86]. In addition to retinal detachment caused by subretinal injections and the release of toxic substances around the treated areas, continued photoreceptor loss is also related to photoreceptor cells having begun the irreversible apoptosis process before treatment [84,87]. It is important to correct the negative effects of gene therapy that appeared in the ongoing clinical trial, and HDACis may be a good option. Considering the fact that HDACis can prevent death of photoreceptor cells and protect retinal damage, we hypothesize that HDACis may play a role in preventing the continuing death of photoreceptor cells after gene therapy and are conducting these experiments.

In this paper, we summarized the neuroprotective effects of common HDACis in retinal degenerative diseases (Figure 1). Currently, clinical trials of VPA in RP have been carried out. As in-depth studies of HDACis, more and more molecular mechanisms of HDACis on neuroprotective effects will be found in retinal degenerative diseases. HDACis can inhibit the apoptosis of photoreceptor cells during retinal damage process; therefore, HDACis may be a group of promising agents to be explored in the prevention of apoptosis of photoreceptors and in the treatment of retinal degenerative diseases.

**Conflict of Interests**

All authors declare no potential conflict of interests related to this paper.

**Authors’ Contribution**

Hua Zhang and Xufeng Dai contributed equally to the work presented here and should therefore be regarded as equivalent authors.

**Acknowledgments**

This work was supported by the National Natural Science Foundation of China (81371060), a retinal gene therapy study grant from Wenzhou Medical University, Wenzhou, China (QTJ11018), the scientific research foundation from Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University (KYQD130501), and the Jiangsu Province Foundation for Innovative Research Team and National Institutes of Health (NIH) grant (EY023543).
References

[1] C. Huang, E. A. Sloan, and C. F. Boerkoel, “Chromatin remodeling and human disease,” Current Opinion in Genetics and Development, vol. 13, no. 3, pp. 246–252, 2003.

[2] C. Simone and A. Peserico, “Physical and functional HAT/HDAC interplay regulates protein acetylation balance,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 371832, 10 pages, 2011.

[3] G. Giannini, W. Cabri, C. Fattorussolo, and M. Rodriguez, “Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives,” Future Medicinal Chemistry, vol. 4, no. 11, pp. 1439–1460, 2012.

[4] M.-J. Chuang, S.-T. Wu, S.-H. Tang et al., “The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation,” PLoS ONE, vol. 8, no. 9, Article ID e73401, 2013.

[5] W. Feng, B. Zhang, D. Cai, and X. Zou, “Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer,” Cancer Letters, vol. 347, no. 2, pp. 183–190, 2014.

[6] D. Khabele, “The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer,” Frontiers in Oncology, vol. 4, article 111, 2014.

[7] M. A. Salvador, J. Wicinski, O. Cabaud et al., “The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression,” Clinical Cancer Research, vol. 19, no. 23, pp. 6520–6531, 2013.

[8] J. M. Mariadason, “HDACs and HDAC inhibitors in colon cancer,” Epigenetics, vol. 3, no. 1, pp. 28–37, 2008.

[9] D. Russo, C. Durante, S. Bulotta et al., “Targeting histone deacetylation in thyroid cancer,” Expert Opinion on Therapeutic Targets, vol. 17, no. 2, pp. 179–193, 2013.

[10] M. Ren, Y. Leng, M. Jeong, P. R. Leeds, and D.-M. Chuang, “Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction,” Journal of Neurochemistry, vol. 89, no. 6, pp. 1358–1367, 2004.

[11] J. K. Hyeon, M. Rowe, M. Ren, J. S. Hong, P. S. Chen, and D. M. Chuang, “Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action,” Journal of Pharmacology and Experimental Therapeutics, vol. 321, no. 3, pp. 892–901, 2007.

[12] D.-M. Chuang, Y. Leng, Z. Marinova, H.-J. Kim, and C.-T. Chiu, “Multiple roles of HDAC inhibition in neurodegenerative conditions,” Trends in Neurosciences, vol. 32, no. 11, pp. 591–601, 2009.

[13] R. J. Ferrante, K. K. Kubilus, J. Lee et al., “Histone deacetylation inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice,” The Journal of Neuroscience, vol. 23, no. 28, pp. 9418–9427, 2003.

[14] Z. Zhang, X. Qin, N. Tong et al., “Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation,” Experimental Eye Research, vol. 94, no. 1, pp. 98–108, 2012.

[15] H. J. Kim, P. Leeds, and D.-M. Chuang, “The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain,” Journal of Neurochemistry, vol. 110, no. 4, pp. 1226–1240, 2009.

[16] S. Yasuda, M.-H. Liang, Z. Marinova, A. Yahyavi, and D.-M. Chuang, “The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons,” Molecular Psychiatry, vol. 14, no. 1, pp. 51–59, 2009.

[17] V. Marigo, “Programmed cell death in retinal degeneration: targeting apoptosis in photoreceptors as potential therapy for retinal degeneration,” Cell Cycle, vol. 6, no. 6, pp. 652–655, 2007.

[18] J. Sancho-Pelluz, B. Arango-Gonzalez, S. Kustermann et al., “Photoreceptor cell death mechanisms in inherited retinal degeneration,” Molecular Neurobiology, vol. 38, no. 3, pp. 253–269, 2008.

[19] M. M. LaVail, D. Yasumura, M. T. Mattfeld et al., “Protection of mouse photoreceptors by survival factors in retinal degenerations,” Investigative Ophthalmology & Visual Science, vol. 39, no. 3, pp. 592–602, 1998.

[20] M. Frasson, S. Picaud, T. Léveillârd et al., “Gliol cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse,” Investigative Ophthalmology and Visual Science, vol. 40, no. 11, pp. 2724–2734, 1999.

[21] M. Dokmanovic, C. Clarke, and P. A. Marks, “Histone deacetylase inhibitors: overview and perspectives,” Molecular Cancer Research, vol. 5, no. 10, pp. 981–989, 2007.

[22] M. Yamaguchi, Y. Tanou-Fujimori, A. Komori et al., “Histone deacetylase 1 regulates retinal neurogenesis in zebrafish by suppressing Wnt ad Notch signaling pathways,” Development, vol. 132, no. 13, pp. 3027–3043, 2005.

[23] G. Lagger, D. O’Carroll, M. Rembold et al., “Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression,” The EMBO Journal, vol. 21, no. 11, pp. 2672–2681, 2002.

[24] D. Bandopadhyay, J. L. Curry, Q. Lin et al., “Dynamic assembly of chromatin complexes during cellular senescence: Implications for the growth arrest of human melanocytic nevi,” Aging Cell, vol. 6, no. 4, pp. 577–591, 2007.

[25] R. Brunmeir, S. Lagger, and C. Seiser, “Histone deacetylase 1 and 2-controlled embryonic development and cell differentiation,” International Journal of Developmental Biology, vol. 53, no. 2-3, pp. 275–289, 2009.

[26] C. L. Zhang, T. A. McKinsey, S. Chang, C. L. Antos, J. A. Hill, and E. N. Olson, “Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy,” Cell, vol. 110, no. 4, pp. 479–488, 2002.

[27] Y. Xiong, K. Zhao, J. Wu, Z. Xu, S. Jin, and Y. Q. Zhang, “HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 12, pp. 4604–4609, 2013.

[28] R. B. Vega, K. Matsuda, J. Oh et al., “Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis,” Cell, vol. 119, no. 4, pp. 555–566, 2004.

[29] I. Koutsonouas, C. Giaginis, E. Patsouris, and S. Theocharis, “Current evidence for histone deacetylase inhibitors in pancreatic cancer,” World Journal of Gastroenterology, vol. 19, no. 6, pp. 813–828, 2013.

[30] M. Yoshida, M. Kijima, M. Akita, and T. Beppu, “Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A,” Journal of Biological Chemistry, vol. 265, no. 28, pp. 17174–17179, 1990.

[31] M. Rahman, A. Kukita, T. Kukita, T. Nakamura, and O. Kohashi, “Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages,” Blood, vol. 101, no. 9, pp. 3451–3459, 2003.
B. Chen and C. L. Cepko, "Requirement of histone deacetylase activity for the expression of critical photoreceptor genes," BMC Developmental Biology, vol. 7, article 4, 2006.

A. Kretsovali, C. Hadjimichael, and N. Charmpilas, "Histone deacetylase inhibitors in adult rat retina," Brain Research Bulletin, vol. 79, no. 6, pp. 342–346, 2011.

C. E. Croston, S. K. Mani, S. Husain, O. Alsarraf, and D. R. Menick, "Inhibition of histone deacetylase protects the retina from ischemic injury," Investigative Ophthalmology and Visual Science, vol. 51, no. 7, pp. 3639–3645, 2010.

J. Fan, O. Alsarraf, M. Dahrouj et al., "Inhibition of HDAC2 protects the retina from ischemic injury," Investigative Ophthalmology and Visual Science, vol. 54, no. 6, pp. 4072–4080, 2013.

H. R. Pelzel, C. L. Schlamp, M. Waclawski, M. K. Shaw, and R. W. Nickells, "Silencing of Fem1cR3 gene expression in the DBA/2J mouse precedes retinal ganglion cell death and is associated with histone deacetylase activity," Investigative Ophthalmology and Visual Science, vol. 53, no. 3, pp. 1428–1435, 2012.

Y. Koriyama, K. Sugitani, K. Ogai, and S. Kato, "Neurotogenic activity of trichostatin α in adult rat retinal ganglion cells through acetylation of histone H3 lysine 9 and RARβ induction," Journal of Pharmacological Sciences, vol. 124, no. 1, pp. 112–116, 2014.

Y. Koriyama, Y. Takagi, K. Chiba et al., "Requirement of retinoic acid receptor β for genipin derivative-induced optic nerve regeneration in adult rat retina," PLoS ONE, vol. 8, Article ID e71252, 2013.

F. Paquet-Durand, J. Silva, T. Talukdar et al., "Excessive activation of poly(ADP-ribose) polymerase contributes to inherited photoreceptor degeneration in the retinal degeneration 1 mouse," Journal of Neuroscience, vol. 27, no. 38, pp. 10311–10319, 2007.

J. Sancho-Pelluz and F. Paquet-Durand, "HDAC inhibition prevents Rdl mouse photoreceptor degeneration," Advances in Experimental Medicine and Biology, vol. 723, pp. 107–113, 2012.
glioma cell proliferation when p21WAF/Cip1 and gelsolin are induced,” *Neuro-Oncology*, vol. 4, no. 2, pp. 95–101, 2002.

[64] X. X. Cao, I. Mohuiddin, F. Ece, D. J. McConkey, and W. R. Smythe, “Histone deacetylase inhibitor downregulation of bel-2xl gene expression leads to apoptotic cell death in mesothelioma,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 25, no. 5, pp. 562–568, 2001.

[65] R. Claus, D. Günthner, and H. Letzguss, “Effects of feeding fat-coated butyrate on mucosal morphology and function in the small intestine of the pig,” *Journal of Animal Physiology and Animal Nutrition*, vol. 91, no. 7–8, pp. 312–318, 2007.

[66] J. Huuskonen, T. Suuronen, T. Nuutinen, S. Kyrölenko, and A. Salminen, “Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids,” *British Journal of Pharmacology*, vol. 141, no. 5, pp. 874–880, 2004.

[67] Q. Zhou, C. L. Dalgard, C. Wynder, and M. L. Doughty, “Histone deacetylase inhibitors SAHA and sodium butyrate block Gi-to-S cell cycle progression in neurosphere formation by adult subventricular cells,” *BMC Neurosciience*, vol. 12, article 50, 2011.

[68] Y. Karasawa and S. Okisaka, “Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells,” *Japanese Journal of Ophthalmology*, vol. 48, no. 6, pp. 542–551, 2004.

[69] G. Faraco, T. Pancani, L. Formentini et al., “Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain,” *Molecular Pharmacology*, vol. 70, no. 6, pp. 1876–1884, 2006.

[70] S. H. Chen, H. M. Wu, B. Ossola et al., “Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage,” *British Journal of Pharmacology*, vol. 165, no. 2, pp. 494–505, 2012.

[71] J. P. Dompierre, J. D. Godin, B. C. Charrin et al., “Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington’s disease by increasing tubulin acetylation,” *Journal of Neuroscience*, vol. 27, no. 13, pp. 3571–3583, 2007.

[72] N. Agrawal, J. Pallos, N. Slepkó et al., “Identification of combinatorial drug regimens for treatment of Huntington’s disease using Drosophila,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 10, pp. 3777–3781, 2005.

[73] A. Tandon, J. C. K. Tovey, M. R. Waggoner et al., “Vorinostat: a potent agent to prevent and treat laser-induced corneal haze,” *Journal of Refractive Surgery*, vol. 28, no. 4, pp. 285–290, 2012.

[74] X. Li, Q. Zhou, J. Hanus et al., “Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model,” *Molecular Pharmacaceutics*, vol. 10, no. 1, pp. 307–318, 2013.

[75] V. Poulaki, C. S. Mitsiades, V. Kotoula et al., “Molecular sequelae of histone deacetylation inhibition in human retinoblastoma cell lines: Clinical implications,” *Investigative Ophthalmology and Visual Science*, vol. 50, no. 9, pp. 4072–4079, 2009.

[76] C. L. Dalgard, K. R. van Quill, and J. M. O’Brien, “Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma,” *Clinical Cancer Research*, vol. 14, no. 10, pp. 3113–3123, 2008.

[77] P. Chindasub, J. D. Lindsey, K. Duong-Polk, C. K. Leung, and R. N. Weinreb, “Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells,” *Investigative Ophthalmology and Visual Science*, vol. 54, no. 1, pp. 96–102, 2013.

[78] M. A. Yenari, J. Liu, Z. Zheng, Z. S. Vexler, J. E. Lee, and R. G. Giffard, “Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection,” *Annals of the New York Academy of Sciences*, vol. 1053, pp. 74–83, 2005.

[79] T. Ichiyama, K. Okada, J. M. Lipton, T. Matsubara, T. Hayashi, and S. Furukawa, “Sodium valproate inhibits production of TNF-α and IL-6 and activation of NF-κB,” *Brain Research*, vol. 857, no. 1-2, pp. 246–251, 2000.

[80] M. Kirsch, S. Schulz-Key, A. Wiese, S. Fuhrmann, and H. D. Hofmann, “Ciliary neurotrophic factor blocks rod photoreceptor differentiation from postmitotic precursor cells in vitro,” *Cell and Tissue Research*, vol. 291, no. 2, pp. 207–216, 1998.

[81] X. Wu, P. S. Chen, S. Dallas et al., “Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons,” *The International Journal of Neuropsychopharmacology*, vol. 11, no. 8, pp. 1123–1134, 2008.

[82] S. Azadi, L. E. Johnson, F. Paquet-Durand et al., “CNTF + BDNF treatment and neuroprotective pathways in the rd1 mouse retina,” *Brain Research*, vol. 1129, no. 1, pp. 116–129, 2007.

[83] A. V. Cideciyan, T. S. Aleman, S. L. Boye et al., “Human gene therapy for RPE65 somerase deficiency activates the retinoid cycle of vision but with slow rod kinetics,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 39, pp. 15112–15117, 2008.

[84] S. G. Jacobson, A. V. Cideciyan, R. Ratnakaram et al., “Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years,” *Archives of Ophthalmology*, vol. 130, no. 1, pp. 9–24, 2012.

[85] J. W. B. Bainbridge, A. J. Smith, S. S. Barker et al., “Effect of gene therapy on visual function in Leber’s congenital amaurosis,” *The New England Journal of Medicine*, vol. 358, no. 21, pp. 2231–2239, 2008.

[86] X. Li, W. Li, X. Dai et al., “Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis,” *Investigative Ophthalmology and Visual Science*, vol. 52, no. 1, pp. 7–15, 2011.

[87] A. V. Cideciyan, S. G. Jacobson, W. A. Beltran et al., “Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 6, pp. E517–E525, 2013.

[88] B. R. Schwechter, L. E. Millet, and L. A. Levin, “Histone deacetylase inhibition-mediated differentiation of RGC-5 cells and interaction with survival,” *Investigative Ophthalmology and Visual Science*, vol. 48, no. 6, pp. 2845–2857, 2007.

[89] X. Song, J. Wang, T. Zheng et al., “LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway,” *Molecular Cancer*, vol. 12, no. 1, article 114, 2013.

[90] J. Savickiene, G. Treigyte, V. Borutinskaite, R. Navakauskiene, and K.-E. Magnusson, “The histone deacetylase inhibitor FK228 up-regulates astrocyte GDNF and BDNF gene transcription and protects dopaminergic neurons,” *Neuro-Oncology*, vol. 4, no. 2, pp. 95–101, 2002.
cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, and Sp1, ” *Journal of Biological Chemistry*, vol. 289, no. 10, pp. 6991–7002, 2014.

[93] I. Svechnikova, P. M. Almqvist, and T. J. Ekström, ”HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin,” *International Journal of Oncology*, vol. 32, no. 4, pp. 821–827, 2008.

[94] Z. Khan, M. Akhtar, and T. J. Ekström, ”HDAC inhibitor 4-phenylbutyrate preserves immature phenotype of human embryonic midbrain stem cells: implications for the involvement of DNA methyltransferase,” *International Journal of Molecular Medicine*, vol. 28, no. 6, pp. 977–983, 2011.